Industrial Pharmacy Advisory Group (IPAG)

RPS Industrial Pharmacy Advisory Group (IPAG) provides a source of expertise on issues of pharmacy practice which impact on patients, the public, and the profession.

IPAG is a consultative group to the Boards of the RPS, acting as a source of expertise and advice, and providing evidenced-based leadership and opinion to inform RPS policy decisions and advice to government and other organisations.

The main aim of IPAG is to provide leadership in practice, identify and track the changing healthcare environment, advise on the implications for the industrial sector and the RPS and also highlight the changing professional needs and competencies of its members.

Read the Terms of Reference for the Industrial Pharmacy Advisory Group (IPAG).


  • Sunayana Shah (Chair)
  • Neel Bhatt
  • Ciara O'Brien
  • Jeremy Clarke
  • Vito Constanza
  • Diar Fattah
  • Sarah Goffin
  • Hari Harrar
  • Pervaise Khan
  • Sue Kilby
  • Yetunde Kolade
  • Jenifer Mains
  • Stephen Makin
  • Ricardo Martinez-Moreno-Davila
  • Jane Nicholson
  • Mine Orlu
  • Marco Picone
  • Kendall Pitt
  • Robert Smith
  • Rebecca Stanbrook
  • Pratik Thakkar

The EIPG newsletter

Read the official newsletter of the European Industrial Pharmacists' Group.

  • Read the March 2021 newsletter
    You may find interesting news for the public consultation on the new HERA agency, the structured dialogue with the EU Commission to prevent shortages, the annual market report for generics from Medicines for Europe, a new report for the future of European biotechnologies.
    You may also read in the News from EIPG about the EIPG and a joint EIPG & EPSA Webinar to be held in May 2021, and the EAFP course VIRT2UE on Research Integrity to be held in April & May 2021, as well as a call for consultation on the draft toolbox guidance to support quality data packages for PRIME MA applications.
    To all of us celebrating Easter, my warmest greetings for you and your loved ones.

  • Read the February 2021 newsletter
    We have a report on the impact of biosimilar competition in Europe, the EMA’s highlights of 2020 (human and veterinary medicines) and the socio-economic impact of Innovative Medicines Initiative (IMI) projects.
    Read the ICH Reflection Paper on Patient-Focused Drug Development (PFDD) which is open to public consultation until 7 March 2021 and aims to favour the involvement of patients in the drug development process by identifying key areas where their contribution may result particularly relevant for the quality, relevance, safety and efficiency of the process, as well as to inform regulatory decision-making.
    Finally, on 9 March 2021 Dr Deavin is providing a summary of the Medical Device Regulations, followed by a question-and-Answer session as many participants could not join the webinar on 3 February, and there were many questions.
    A Joint Statement on future modifications to the Directive on the Recognition of Professional Qualifications has been discussed at length with our European partners.

  • Read the January 2021 newsletter
    What are the trends in API's development for 2021, the new joint EMA & HMA's regulatory strategy for the next five years, and how the Pharmaceutical industry will deal all the necessary changes from Brexit. The digital transformation of the Pharmaceutical Industry is a fact and this issue has the survey run by The Reuters and Omnipresence which analysed how the COVID-19 pandemic favoured that transformation.
    The European Medicines Agency (EMA) issued a draft guidance for consultation explaining how sponsors can pursue a parallel Article 58 (EU-M4all) opinion.
    And the General Pharmaceutical Council (GPhC) has approved new standards for the initial education and training (IET) of pharmacists in the UK. 

  • Read the December 2020 newsletter
    An article on Logistic challenges in the pharma industry due to COVID-19 from our colleague Gina Gal on behalf of the Hungarian Society for Pharmaceutical Sciences (MGYT). The COVID-19 pandemic resulted in many disruptions of the pharmaceutical supply chains, both at the international and EU cross-borders levels. The implementation of new models to handle logistics in this essential sector may represent an opportunity for the future.
    In the December issue you may also read a reflection message on a COVID-19 year by Giorgos Panoutsopoulos, Vice-president Communications of EIPG. Mr. Maurizio Battistini EIPG Vice-President European Affairs was invited to participate in a webinar entitled Diversification of the medicines supply chain in the context of medicine shortages, co-organised by GIRP, EAHP, and PGEU.

  • Read the November 2020 newsletter
    An interesting article from Dr Anthia A Zammit discusses Developments in Article 126a Authorisations in Malta. The related authorisation procedure has changed since 1 October 2020, and Article 126a is now considered as a last-resort, if no other authorisation procedure is available. Thanks to Dr Zammit for this detailed article and and our president, Professor Claude Farrugia, for his valuable contribution, too.
    On Tuesday 24 November 2020 we held our last webinar of 2020, on Advanced Therapy Medicinal Products, chaired by EIPG executive director, Jane Nicholson, and held in conjunction with PIER and University College Cork. Professor Gino Martini, past EIPG president and current RPS Chief Scientist, reflected on the role of pharmacy during COVID-19. Some of the key findings are related to the Pharma sector and other activities involving pharmaceutical or health products.
    Please send me your report of dissemination by the middle of December, and stay close to your loved ones while keeping your distance against COVID-19!

  • Read the October 2020 newsletter
    October's EIPG monthly newsletter has an interesting article on the future of health systems. COVID-19 has brought many initiatives to improve European health policy coordination. The EU intends to reinforce and empower both the European Medicines Agency (EMA) and the European Center for Disease Control and Prevention (ECDC) to improve crisis preparedness and management of cross-border health threats. They also plan a new agency for biomedical advanced research and development, a “European BARDA” modelled on the US agency.
    With an 20-fold increase in shortages between 2000 and 2018, and considering the dependencies of pharma imports from China and India, The European response to the shortage of medicines must be based on three pillars: a return to health sovereignty by securing supplies, stepping up European action to better coordinate and supplement member state health policies, and enhancing cooperation between them, said the EU Parliament.
    Please send me your report of dissemination by the middle of November and stay safe!

  • Read the September 2020 newsletter
  • The latest issue of EIPG's monthly newsletter has an article from AFI’s national delegate and our Vice-President Technical and Professional Development, Piero Iamartino on how AFI's activities have continued during the COVID-19 emergency.
    Earlier in September, at an EIPG–Tecniche Nuove webinar, Dr Francesco Boschi summarised the most relevant comments to the V12 draft document of Annex 1 (appendix of Eudralex Vol. 4 EU GMP) as developed by the EIPG national working groups. Professor Gino Martini, Chief Scientific Officer for the Royal Pharmaceutical Society and former EIPG President was the main speaker at a joint EIPG & EPSA webinar Innovation and the Pharmacist – putting pharmacy at the forefront of healthcare.
    Please send me your report of dissemination by mid-October and, stay safe and protected against COVID-19!
  • Read the July 2020 newsletter
    EIPG's July newsletter has an article from our colleagues in Belgium. Alexia Rensonent and Thomas Lion, both board members of the Belgian UPIP-VAPI Industrial Pharmacists Association, they tell us about COVID-19's effect on freelance QP and RP-GDP activities.
    You'll also find a short report from EIPG’s first ever digital General Assembly held on 18th of July 2020, through our new communication platform. This year’s General Assembly in Leiden, the Netherlands and hosted by NIA, our Dutch Association, had to be postponed.
    Please send me your dissemination reports by the middle of August 2020, and I wish you all a nice, safe summer!

  • Read the June 2020 newsletter
    EIPG's monthly newsletter for June has an interesting article on Latvia’s new Medicines reimbursement system and Medicinal Products Register prepared with the valuable contribution of the Pharmacists’ Society of Lavia (LFB) and their President Linda Meška.
    You can also read about the decision of EIPG Bureau to hold a digital General Assembly on 18 July as the General Assembly due to be held in the Netherlands and hosted by our Dutch colleagues of NIA has been postponed due to COVID-19 situation.
    Please forward this issue to your members of your association occupied in pharmaceutical industry and allied companies and confirm your dissemination until 15 July 2020.

  • Read the May 2020 newsletter
    The May issue of EIPG's monthly newsletter has an interesting article on how COVID-19 has redesigned the job market at a deep level, and what are the skills pharma worforce is expected to possess to face a still uncertain future.
    Analysis is presented from consultancy firms on how CHROs should look at the new scenarios to sustain both business activities and the need for some employees to find a new position.
    Also, Professor Gino Martini, Chief Scientist for the Royal Pharmaceutical Society in Great Britain talks about the latest issues, innovations and developments in the pharmaceutical sciences and research.
    And finally, a look at the still open consultations on Annex 21 and Annex 1.

  • Read the April 2020 newsletter
  • Read the March 2020 newsletter
  • Read the February 2020 newsletter
  • Read the January 2020 newsletter
  • Read the December 2019 newsletter
  • Read the November 2019 newsletter
  • Read the October 2019 newsletter
  • Read the September 2019 newsletter
  • Read the August 2019 newsletter
  • Read the July 2019 newsletter
  • Read the June 2019 newsletter